NLM Digital Collections

Search

Start Over Subjects Urinary Bladder Neoplasms -- drug therapy ✖Remove constraint Subjects: Urinary Bladder Neoplasms -- drug therapy Titles Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report ✖Remove constraint Titles: Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report

1. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report

Author(s):
Atlas, Steven J., author
Touchette, Daniel R., author
Beinfeld, Molly, author
McKenna, Avery, author
Joshi, Mrinmayee, author
Chapman, Rick M., author
Pearson, Steven D., author
Rind, David M., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, January 15, 2021
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Urinary Bladder Neoplasms -- drug therapy
Genetic Vectors -- therapeutic use
United States

Refine by:

more »

  • Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report1